List of Excipients in Branded Drug INTELENCE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
State of Florida DOH Central Pharmacy	INTELENCE	etravirine	53808-0787	CELLULOSE, MICROCRYSTALLINE
State of Florida DOH Central Pharmacy	INTELENCE	etravirine	53808-0787	CROSCARMELLOSE SODIUM
State of Florida DOH Central Pharmacy	INTELENCE	etravirine	53808-0787	HYPROMELLOSE

Intelence Excipient Strategy and Commercial Opportunities for Etravirine

Last updated: August 1, 2026

Intelence, the branded etravirine product from Janssen, is an oral non-nucleoside reverse transcriptase inhibitor for treatment-experienced patients with HIV-1 infection. Its commercial opportunity is no longer based on premium branded pricing. The strongest opportunities are in generic substitution, low-cost HIV access, pediatric dose flexibility, formulation simplification, and excipient-controlled manufacturing.

Etravirine has poor aqueous solubility and requires administration after a meal. Its formulation therefore depends on tablet disintegration, wetting, particle dispersion, and consistent dissolution rather than on a simple direct-compression excipient system. The core commercial challenge is to reproduce bioavailability while reducing manufacturing cost and managing food-effect performance.

What excipients are used in Intelence tablets?

Intelence tablets use conventional oral solid-dose excipients, with different strengths allowing dose flexibility for treatment-experienced HIV patients.

Component	Function in the formulation	Commercial relevance
Microcrystalline cellulose	Filler, dry binder, compression aid	Supports tablet hardness and manufacturability
Croscarmellose sodium	Superdisintegrant	Promotes rapid tablet breakup and drug exposure
Hypromellose	Binder or film-forming polymer	Controls tablet structure and coating performance
Colloidal silicon dioxide	Glidant and moisture-control aid	Improves powder flow and blend uniformity
Magnesium stearate	Lubricant	Reduces sticking and ejection force
Film-coating materials	Protection, appearance, swallowability, identification	May affect stability, moisture protection, and patient acceptance

The FDA prescribing information identifies these excipient classes for Intelence tablets. Exact quantitative composition and manufacturing parameters are not generally disclosed in the public product label.[1]

Which strengths does Intelence have?

Intelence is marketed in 25 mg, 100 mg, and 200 mg tablet strengths. The recommended adult dose is 200 mg twice daily with food. The 25 mg and 100 mg strengths support pediatric dosing and dose adjustment, while the 200 mg tablet can reduce pill burden in eligible patients.[1]

The multiple-strength architecture creates a commercial opportunity for generic manufacturers that can offer:

• A complete 25 mg, 100 mg, and 200 mg portfolio.
• A 100 mg tablet that permits flexible titration.
• A 200 mg tablet optimized for lower pill burden.
• Pediatric packaging with dose instructions and adherence support.
• Unit-dose blister packaging for HIV treatment programs.

How does etravirine’s solubility affect excipient selection?

Etravirine is a poorly water-soluble drug. Its oral exposure depends on formulation performance and food intake. The tablet must disintegrate efficiently and present the drug to gastrointestinal fluids in a form capable of dissolving and being absorbed.

The main formulation risks are:

1. Inadequate wetting of the hydrophobic drug.
2. Slow dissolution after tablet disintegration.
3. Blend segregation caused by low-dose drug loading.
4. Over-lubrication from excessive magnesium stearate.
5. Batch-to-batch variation in particle size and solid form.
6. Loss of dissolution performance when manufacturing scale changes.

Microcrystalline cellulose and croscarmellose sodium provide a conventional starting platform. A generic developer may need to optimize particle size, granulation method, disintegrant location, lubricant concentration, and compression force. A formulation that meets hardness and friability specifications can still fail comparative dissolution if the drug remains poorly wetted.

Is a simple generic formulation sufficient?

Not necessarily. A conventional excipient substitution can be commercially viable if the applicant demonstrates pharmaceutical equivalence, dissolution similarity, stability, and bioequivalence. The formulation becomes more complex when the reference product has a narrow dissolution profile or when the applicant seeks to reduce food dependence.

Potential development routes include:

• Wet granulation to improve content uniformity and compactability.
• Dry granulation to reduce water exposure and manufacturing complexity.
• Superdisintegrant optimization to accelerate tablet breakup.
• Surfactant incorporation to improve wetting.
• Particle engineering to control etravirine surface area.
• Amorphous or solid-dispersion approaches to increase apparent solubility.
• Lipid-based or self-emulsifying systems where conventional tablet approaches are inadequate.

Each route creates different regulatory and intellectual-property consequences. A conventional tablet may be easier to register but harder to differentiate. A solubility-enhanced formulation may improve performance but create new patent exposure and additional stability work.

What formulations are commercially attractive for etravirine?

The strongest near-term opportunity is a conventional immediate-release tablet that matches Intelence dissolution and bioavailability at materially lower cost.

Formulation concept	Development difficulty	Commercial value	IP exposure
Conventional immediate-release tablet	Low to moderate	High for generic substitution	Lower
High-strength 200 mg tablet	Moderate	High because of lower pill burden	Moderate
Pediatric 25 mg tablet	Moderate	High in pediatric and public-sector channels	Moderate
Orally disintegrating tablet	Moderate to high	Niche adherence opportunity	Potentially higher
Sprinkle or dispersible tablet	High	Pediatric and dysphagia opportunity	Potentially higher
Solubility-enhanced tablet	High	Could reduce food-effect limitations	Higher
Fixed-dose combination	Very high	Large commercial upside if clinically and technically feasible	High

A dispersible or orally disintegrating formulation could address patients with swallowing difficulties, pediatric use, or adherence barriers. The commercial value would depend on whether the formulation improves administration without increasing tablet size, taste burden, or manufacturing cost.

A fixed-dose combination involving etravirine would face substantial clinical and regulatory constraints. Etravirine is generally used in treatment-experienced regimens selected according to resistance testing. That treatment pattern makes a broad fixed-dose combination less straightforward than combinations used in first-line HIV therapy.

When did Intelence lose regulatory exclusivity?

Intelence was approved by the FDA in 2008 under NDA 22-187.[1] Its five-year new chemical entity exclusivity period expired before the end of the 2010s. Etravirine is a small molecule, so biosimilar exclusivity rules do not apply.

Protection category	Intelence status
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not the primary protection mechanism
Pediatric exclusivity	Any extension was time-limited and has expired
Biologic exclusivity	Not applicable
Small-molecule patent protection	Must be assessed through live jurisdiction-specific records
Generic pathway	ANDA pathway is potentially available, subject to applicable listings and certifications

Regulatory exclusivity and patent protection are separate. Expiration of NCE exclusivity does not by itself establish immediate generic launch freedom. A generic applicant must evaluate Orange Book listings, patent certifications, litigation risk, and any settlement restrictions.

What is the Orange Book status of Intelence?

Intelence is listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, under etravirine and NDA 22-187.[2]

The relevant commercial questions are:

• Whether any patents remain listed for the specific dosage forms.
• Whether listed patents cover the active ingredient, formulation, or method of use.
• Whether a generic applicant would file a Paragraph III or Paragraph IV certification.
• Whether the reference sponsor has submitted patent information or changes to the listing.
• Whether an ANDA applicant has received a 30-month stay from patent litigation.

Orange Book status can change through patent listing updates, delisting, litigation, or administrative correction. The Orange Book should be reviewed against the current FDA record before an ANDA filing or launch decision.[2]

What patent claims could affect etravirine generic entry?

The patent analysis should separate four claim groups.

Active-ingredient and compound claims

Compound patents are generally the most important historic barrier because they can cover etravirine itself or a class of diarylpyrimidine compounds. Their commercial value depends on expiration, terminal disclaimers, patent-term adjustment, pediatric extensions, and jurisdiction.

Formulation patents

Formulation claims may cover:

• Specific excipient combinations.
• Particle-size distributions.
• Dissolution characteristics.
• Solid-state forms.
• Amorphous etravirine.
• Drug-polymer dispersions.
• Taste-masking or dispersible dosage forms.
• Manufacturing processes that produce a defined release profile.

A generic using a conventional formulation may avoid formulation claims that require a specific polymer, ratio, or solid form. A differentiated product using enhanced solubility technology may create a new patent estate but increase freedom-to-operate risk.

Method-of-use patents

Etravirine’s label includes use in combination with other antiretroviral agents for treatment-experienced HIV-1 patients with resistance.[1] Method-of-use patents can create skinny-label or carve-out issues if they remain enforceable and are listed for the ANDA product.

A generic applicant must assess whether the proposed label includes the patented indication, dosing regimen, patient population, or combination use. In HIV, label design is particularly important because treatment decisions are often individualized according to resistance history.

Manufacturing patents

Manufacturing claims can cover:

• Crystallization conditions.
• Polymorph control.
• Milling and particle-size reduction.
• Granulation parameters.
• Solvent systems.
• Scale-up methods.
• Impurity control.

These rights can matter even when composition-of-matter patents have expired. Manufacturing patents are less likely to block a product outright if a practical non-infringing process is available, but they can increase development cost and delay technology transfer.

What Paragraph IV challenges and litigation affect Intelence?

A Paragraph IV certification asserts that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed by the proposed ANDA product. A first Paragraph IV filer may obtain 180-day generic exclusivity if statutory conditions are met.

Publicly available Intelence information does not establish a current, active litigation event that determines the entire etravirine market. Any launch assessment should distinguish among:

Issue	Business impact
Historical patent litigation	May explain prior generic timing and settlement terms
Active ANDA litigation	Can trigger a 30-month stay
Patent settlement	May establish a licensed or restricted launch date
Patent expiration	Usually removes the relevant statutory barrier
Unlisted formulation patent	May support later infringement litigation but may not trigger an Orange Book stay
Skinny-label approval	Can reduce method-of-use exposure

Settlement agreements are particularly important because a patent expiry date does not always equal the earliest commercial launch date. Agreements may include authorized-generic rights, supply obligations, launch licenses, or restrictions tied to particular strengths.

No reliable commercial conclusion should be drawn from the absence of a publicly visible dispute alone. ANDA litigation records, FDA patent listings, SEC disclosures, and court dockets should be read together.

Is there biosimilar risk for Intelence?

No. Intelence contains etravirine, a chemically synthesized small molecule. Biosimilar approval under the Public Health Service Act does not apply.

The relevant competitive risk is from:

• Etravirine ANDA products.
• Authorized generics.
• Regional generic manufacturers.
• Public-sector suppliers.
• Alternative antiretroviral regimens.
• Newer agents with better resistance profiles or simpler dosing.

The largest long-term threat is therapeutic substitution. Etravirine is used mainly in treatment-experienced patients, and clinicians may select newer agents when resistance, tolerability, drug interactions, or dosing convenience favor another regimen.

Which companies are likely to challenge Intelence?

The most credible challengers are established generic manufacturers with HIV manufacturing and regulatory capabilities. Potential participants include large multinational generic companies, specialist antiretroviral suppliers, and manufacturers active in Global Fund, PEPFAR, or other procurement channels.

The commercial qualification criteria are more important than company name:

• Prior ANDA experience with poorly soluble tablets.
• Capability to produce multiple strengths.
• HIV product registration in the United States or major emerging markets.
• Access to low-cost high-containment or high-potency manufacturing.
• Stability data under climatic zone IV conditions.
• Ability to meet procurement documentation requirements.
• Capacity for pediatric and institutional packaging.

A manufacturer that can develop only a 200 mg tablet may capture part of the market but lose pediatric and dose-flexibility tenders.

How strong is the Intelence patent estate?

The historic estate was strongest around the active ingredient and early clinical use. Its present commercial strength depends on the surviving claims, expiration dates, listed patents, and any enforceable formulation or manufacturing rights.

Estate component	Relative strategic importance
Etravirine compound claims	Historically very high; now primarily an expiry and jurisdiction question
Original treatment-use claims	Moderate, depending on enforceability and label scope
Tablet formulation claims	Moderate; highly relevant to design-around analysis
Pediatric or dispersible formulations	Potentially high for differentiated products
Manufacturing claims	Moderate; usually manageable through process redesign
Trade secrets and know-how	Important for scale-up and impurity control

The most defensible commercial strategy is a clean-room generic formulation based on public regulatory information and independent process development. Copying a reference-product manufacturing process creates unnecessary risk when the desired commercial product is an immediate-release tablet that can be built around standard excipients.

What commercial opportunities exist beyond a standard generic?

Low-cost HIV procurement

Etravirine may have value in markets where treatment-experienced patients require a resistance-compatible regimen and newer agents are unavailable or unaffordable. A generic supplier can compete through tender pricing, supply reliability, and climatic stability rather than brand positioning.

Pediatric dosing

The 25 mg and 100 mg strengths create a specific opportunity in pediatric HIV treatment. Commercial differentiation can come from smaller tablets, dispersibility, child-resistant but caregiver-friendly packaging, and simplified weight-band instructions.

Regional registration

Opportunities may exist in jurisdictions where Intelence or generic etravirine has limited competition. Geographic strategy should account for:

• Local patent expiry.
• Data exclusivity.
• Local registration requirements.
• Public procurement demand.
• HIV treatment guidelines.
• Importation rules.
• Local manufacturing incentives.

US approval does not establish freedom to launch in Europe, Canada, Latin America, Africa, or Asia. Patent and regulatory rights must be analyzed country by country.

Contract manufacturing and licensing

A specialty pharmaceutical company could license:

• Etravirine drug substance.
• A validated tablet process.
• A pediatric dosage form.
• A dispersible formulation.
• Regional marketing rights.
• Public-sector supply rights.

The most practical deal structure is likely to be a regional commercialization license or supply agreement rather than a global brand acquisition. The product’s mature lifecycle makes manufacturing economics and procurement access more important than large front-loaded royalties.

How does Intelence compare with competing HIV products?

Product category	Competitive advantage over etravirine	Etravirine’s remaining advantage
Integrase inhibitor regimens	Simpler dosing, strong current guideline positioning	Activity in selected resistant-virus settings
Protease inhibitor regimens	Different resistance and interaction profiles	Oral tablet option for treatment-experienced patients
Other NNRTIs	Familiar class and possible lower cost	Etravirine may retain activity against some NNRTI-resistant virus
Long-acting injectable therapy	Adherence advantage for eligible patients	No injection infrastructure required
Generic antiretroviral combinations	Lower pill burden and procurement simplicity	Etravirine can fill a resistance-driven niche

Etravirine’s commercial market is therefore narrower than that of first-line antiretroviral products. A generic program should not assume that low price alone will create broad demand. Forecasting should use treatment-experienced patient counts, resistance patterns, guideline placement, and tender volumes.

What revenue exposure does Intelence have?

Janssen does not generally report Intelence revenue as a separately material public segment in its principal financial disclosures. The product’s revenue exposure is therefore best assessed through prescription data, formulary position, tender awards, distributor sales, and antiretroviral treatment volumes rather than through a disclosed standalone figure.

For a generic entrant, the relevant revenue model is:

1. Addressable treatment-experienced population.
2. Share of patients receiving etravirine.
3. Number of tablets per patient per year.
4. Net price after tender discounts.
5. Number of competing suppliers.
6. Probability and timing of generic entry.
7. Manufacturing cost by strength.
8. Working-capital requirements for public-sector contracts.

The 200 mg strength may carry the highest volume efficiency, while the 25 mg strength may have disproportionate strategic value for pediatric tenders and portfolio completeness.

Key Takeaways

• Intelence contains etravirine, a poorly soluble small-molecule antiretroviral.
• Its tablet platform uses conventional excipients, including microcrystalline cellulose, croscarmellose sodium, hypromellose, colloidal silicon dioxide, and magnesium stearate.[1]
• The main technical challenge is matching dissolution and exposure while managing the known requirement to take etravirine with food.
• The strongest generic opportunity is a conventional immediate-release tablet in 25 mg, 100 mg, and 200 mg strengths.
• Pediatric, dispersible, and adherence-oriented formulations offer differentiation but create greater development and patent risk.
• Biosimilar competition is irrelevant; the competitive threat is from ANDA products, regional generics, authorized generics, and therapeutic substitution.
• Orange Book listings and patent certifications must be checked before launch planning because regulatory exclusivity, patent expiry, and settlement-based launch rights are separate issues.[2]
• The most defensible commercial route is an independently developed generic process using standard excipients and a jurisdiction-specific freedom-to-operate analysis.
• Revenue potential is likely concentrated in specialized treatment-experienced HIV populations and public-sector procurement rather than broad first-line therapy.

Frequently Asked Questions

Can etravirine be formulated without the Intelence excipients?

Yes. Generic manufacturers can use different inactive ingredients if the product meets applicable pharmaceutical equivalence, quality, dissolution, stability, labeling, and bioequivalence requirements.

Does etravirine require a solubility-enhancing excipient?

Not necessarily. Intelence uses a conventional tablet platform, but formulation development must address etravirine’s poor aqueous solubility and food-dependent exposure. A solubility-enhancing system may be useful for differentiated products.

Is a 200 mg etravirine tablet commercially preferable to lower strengths?

The 200 mg strength can reduce pill burden for adult patients receiving the recommended dose. The 25 mg and 100 mg strengths remain important for pediatric dosing and regimen flexibility.

Can an etravirine generic use a skinny label?

Potentially. A skinny-label strategy may omit patented methods of use if the omitted indication or use can be carved out under FDA requirements. The proposed label must be assessed against current Orange Book listings and applicable patent claims.

Are Intelence formulation patents more important than compound patents?

For a current generic program, formulation and manufacturing patents may be more relevant if the original compound claims have expired in the target jurisdiction. Their impact depends on claim scope, expiry, enforceability, and whether the generic formulation practices the claimed features.

References

1. U.S. Food and Drug Administration. (2024). Intelence (etravirine) tablets: Prescribing information. Janssen Products, LP.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (2024). Guidance for industry: Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA. FDA Center for Drug Evaluation and Research.

4. U.S. Department of Health and Human Services. (2024). HIV treatment guidelines: What to start: Initial combination antiretroviral regimens. National Institutes of Health.

5. U.S. Food and Drug Administration. (2008). FDA approves Intelence for treatment-experienced patients with HIV-1 infection. FDA.